Compare SHIM & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | YARW |
|---|---|---|
| Founded | 1990 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 114.6M |
| IPO Year | 2023 | 2017 |
| Metric | SHIM | YARW |
|---|---|---|
| Price | $2.52 | $19.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 130.1K | 100.4K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $492,844,000.00 | N/A |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.95 | $18.16 |
| 52 Week High | $6.76 | $44.28 |
| Indicator | SHIM | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 28.76 | 33.61 |
| Support Level | $2.45 | $18.24 |
| Resistance Level | $4.09 | $32.89 |
| Average True Range (ATR) | 0.20 | 1.88 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 10.81 | 19.22 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.